Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cavit-XT is a multi-ingredient nutritional supplement and pharmaceutical formulation developed and marketed by Cachet Pharmaceuticals, a subsidiary of Alkem Laboratories. It is designed to treat and prevent nutritional deficiencies, particularly those affecting bone health and neurological function. The formulation is a combination tablet containing Calcium Carbonate, Vitamin D3 (Cholecalciferol), Methylcobalamin (Vitamin B12), L-Methylfolate Calcium (Vitamin B9), and Pyridoxal-5-phosphate (Vitamin B6). It is commonly prescribed for patients with low blood calcium levels, osteoporosis, or conditions where dietary intake is insufficient to meet the body's requirements for these essential vitamins and minerals. The components work synergistically to support bone density, intestinal calcium absorption, and healthy homocysteine metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cavit-XT.